Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX1 | P07099 | 1/20 | 0.46 |
| ▸ | ATM | Q13315 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 14/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.43 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11100479 | 0.81 | EPHX1 (0.52) | EPHX1ATMACHEALDH1A1HPGD | |
| Ammonia Solution, Strong SCHEMBL27626603 | 0.79 | EPHX1 (0.50) | EPHX1ATMACHEALDH1A1HPGD | |
| SCHEMBL9264188 | 0.79 | EPHX1 (0.46) | EPHX1ATMACHEALDH1A1 | |
| SCHEMBL2487393 | 0.76 | EPHX1 (0.47) | EPHX1ATMACHEALDH1A1HCAR2 | |
| SCHEMBL6318148 | 0.76 | EPHX1 (0.47) | EPHX1ATMACHEALDH1A1HPGD | |
| SCHEMBL31759054 | 0.76 | EPHX1 (0.47) | EPHX1ATMACHEALDH1A1HPGD | |
| SCHEMBL21059108 | 0.76 | EPHX1 (0.60) | EPHX1ACHE | |
| SCHEMBL2486965 | 0.75 | EPHX1 (0.46) | EPHX1ATMACHEALDH1A1HPGD | |
| SCHEMBL7773641 | 0.75 | EPHX1 (0.46) | EPHX1ATMACHEALDH1A1HPGD | |
| SCHEMBL7773645 | 0.75 | ALDH1A1 (0.48) | EPHX1ATMACHEALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | PI INDUSTRIES LTD. (IN) | 2025-02-13 | — | — | US | disclosed |
| EP-1232153-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM PLC (GB) | 2002-08-21 | — | — | EP | disclosed |
| WO-2001038324-A2 | IMIDAZOLE DERIVATIVES AND THEIR USE AS RAF KINASE INHIBITORS | SMITHKLINE BEECHAM P.L.C. (GB) | 2001-05-31 | — | — | WO | disclosed |
| EP-0805816-A1 | COMPOUNDS WITH GROWTH HORMONE RELEASING PROPERTIES | NOVO NORDISK A/S (DK) | 1997-11-12 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250049036-A1 | SUBSTITUTED FUSED BICYCLIC PYRIDINE CARBOXAMIDE COMPOUNDS FOR COMBATING PHYTOPATHOGENIC FUNGI | CBR3, C5, CBR1 | EPHX1 2468/4885ATM 3450/4885ACHE 2945/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.